Literature DB >> 16231180

Expression of apoptosome pathway-related transcripts in non-small cell lung cancer.

Evzen Krepela1, Jan Procházka, Pavel Fiala, Petr Zatloukal, Pavel Selinger.   

Abstract

PURPOSE: Tumour cells killing by cytotoxic therapies largely depends on triggering the intrinsic apoptosome-mediated caspase activation pathway but it had never been evaluated whether the expression of transcripts encoding the core components of apoptosome pathway is altered in non-small cell lung carcinoma (NSCLC).
METHODS: We investigated the expression status of several apoptosome pathway-related transcripts including Apaf-1, procaspase-9, -3, -6, -7 and Smac in tumour and lung tissue samples from 65 surgically treated NSCLC patients and in 10 NSCLC cell lines with using real time RT-PCR.
RESULTS: NSCLC tissues and cell lines showed significantly increased expression of procaspase-9, -3, -6 and Smac mRNAs as compared to the lungs and expression of these transcripts was simultaneously upregulated in a subset of NSCLCs belonging to different histopathological type, grade and stage categories. The expression of procaspase-7 mRNA in NSCLC tissues and cell lines and lungs was not significantly different. By contrast, the expression of Apaf-1 mRNA was frequently downregulated in the tumours as compared to matched lungs. Nevertheless, the examined NSCLC cell lines showed significantly higher expression of Apaf-1 mRNA than the lungs. The expression of Apaf-1, procaspase-9 and -6 mRNAs was higher in lung adenocarcinomas as compared to squamous cell lung carcinomas but the expression levels of the studied apoptosome pathway-related transcripts in the tumours were independent of tumour's grade and stage.
CONCLUSIONS: The results of the present study suggest that there is a subgroup of NSCLCs, which may be intrinsically primed for apoptosis through upregulated expression of transcripts encoding the apoptosome pathway components.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16231180     DOI: 10.1007/s00432-005-0048-6

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  47 in total

1.  Mitochondrial damage prior to apoptosis in furanonaphthoquinone treated lung cancer cells.

Authors:  Eriko Simamura; Kei-Ichi Hirai; Hiroki Shimada; Jiehong Pan; Junko Koyama
Journal:  Cancer Detect Prev       Date:  2003

2.  Direct coupling of the cell cycle and cell death machinery by E2F.

Authors:  Zaher Nahle; Julia Polakoff; Ramana V Davuluri; Mila E McCurrach; Matthew D Jacobson; Masashi Narita; Michael Q Zhang; Yuri Lazebnik; Dafna Bar-Sagi; Scott W Lowe
Journal:  Nat Cell Biol       Date:  2002-11       Impact factor: 28.824

3.  Subunit structures and stoichiometries of human DNA fragmentation factor proteins before and after induction of apoptosis.

Authors:  Piotr Widlak; Joanna Lanuszewska; Robert B Cary; William T Garrard
Journal:  J Biol Chem       Date:  2003-05-14       Impact factor: 5.157

Review 4.  Transcriptional control of the core cell-death machinery.

Authors:  Sharad Kumar; Dimitrios Cakouros
Journal:  Trends Biochem Sci       Date:  2004-04       Impact factor: 13.807

Review 5.  Apoptosome dysfunction in human cancer.

Authors:  K M Hajra; J R Liu
Journal:  Apoptosis       Date:  2004-11       Impact factor: 4.677

6.  Mitochondrial release of pro-apoptotic proteins: electrostatic interactions can hold cytochrome c but not Smac/DIABLO to mitochondrial membranes.

Authors:  Rachel T Uren; Grant Dewson; Christine Bonzon; Trevor Lithgow; Donald D Newmeyer; Ruth M Kluck
Journal:  J Biol Chem       Date:  2004-11-09       Impact factor: 5.157

7.  Endogenously released Smac is insufficient to mediate cell death of human lung carcinoma in response to etoposide.

Authors:  Babett Bartling; Rolf Lewensohn; Boris Zhivotovsky
Journal:  Exp Cell Res       Date:  2004-08-01       Impact factor: 3.905

8.  Increased expression of Apaf-1 and procaspase-3 and the functionality of intrinsic apoptosis apparatus in non-small cell lung carcinoma.

Authors:  Evzen Krepela; Jan Procházka; Xiaoyi Liul; Pavel Fiala; Zdenĕk Kinkor
Journal:  Biol Chem       Date:  2004-02       Impact factor: 3.915

9.  Nuclear localization of apoptosis protease activating factor-1 predicts survival after tumor resection in early-stage non-small cell lung cancer.

Authors:  Benjamin Besse; Céline Candé; Jean-Philippe Spano; Antoine Martin; David Khayat; Thierry Le Chevalier; Thomas Tursz; Laure Sabatier; Jean-Charles Soria; Guido Kroemer
Journal:  Clin Cancer Res       Date:  2004-09-01       Impact factor: 12.531

10.  Autocrine motility factor signaling induces tumor apoptotic resistance by regulations Apaf-1 and Caspase-9 apoptosome expression.

Authors:  Arayo Haga; Tatsuyoshi Funasaka; Yasufumi Niinaka; Avraham Raz; Hisamitsu Nagase
Journal:  Int J Cancer       Date:  2003-12-10       Impact factor: 7.396

View more
  10 in total

1.  Apoptosis-Related Single Nucleotide Polymorphisms and the Risk of Non-Small Cell Lung Cancer in Women.

Authors:  Anand Pathak; Angela S Wenzlaff; Paula L Hyland; Michele L Cote; Greg R Keele; Susan Land; Matthew L Boulton; Ann G Schwartz
Journal:  J Cancer Ther Res       Date:  2014

2.  Removal of Metabolic Liabilities Enables Development of Derivatives of Procaspase-Activating Compound 1 (PAC-1) with Improved Pharmacokinetics.

Authors:  Howard S Roth; Rachel C Botham; Steven C Schmid; Timothy M Fan; Levent Dirikolu; Paul J Hergenrother
Journal:  J Med Chem       Date:  2015-04-20       Impact factor: 7.446

3.  Dysregulated Expression of Apoptosis-Associated Genes and MicroRNAs and Their Involvement in Gastric Carcinogenesis.

Authors:  Mayara Luciana Sallas; Diana Zapparoli; Mônica Pezenatto Dos Santos; Jéssica Nunes Pereira; Wilson Aparecido Orcini; Rita Luiza Peruquetti; Elizabeth Suchi Chen; Marilia de Arruda Cardoso Smith; Spencer Luiz Marques Payão; Lucas Trevizani Rasmussen
Journal:  J Gastrointest Cancer       Date:  2021-06

4.  Procaspase-3 Overexpression in Cancer: A Paradoxical Observation with Therapeutic Potential.

Authors:  Matthew W Boudreau; Jessie Peh; Paul J Hergenrother
Journal:  ACS Chem Biol       Date:  2019-07-16       Impact factor: 5.100

5.  Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities.

Authors:  Howard S Roth; Paul J Hergenrother
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

Review 6.  Putting the pieces together: How is the mitochondrial pathway of apoptosis regulated in cancer and chemotherapy?

Authors:  Rana Elkholi; Thibaud T Renault; Madhavika N Serasinghe; Jerry E Chipuk
Journal:  Cancer Metab       Date:  2014-10-06

7.  Quinacrine inhibits GSTA1 activity and induces apoptosis through G1/S arrest and generation of ROS in human non-small cell lung cancer cell lines.

Authors:  Makhan Kumar; Ansie Martin; Snehal Nirgude; Bibha Chaudhary; Sukanta Mondal; Angshuman Sarkar
Journal:  Oncotarget       Date:  2020-05-05

8.  A constitutively active and uninhibitable caspase-3 zymogen efficiently induces apoptosis.

Authors:  Jad Walters; Cristina Pop; Fiona L Scott; Marcin Drag; Paul Swartz; Carla Mattos; Guy S Salvesen; A Clay Clark
Journal:  Biochem J       Date:  2009-12-10       Impact factor: 3.857

9.  Evaluation of a procaspase-3 activator with hydroxyurea or temozolomide against high-grade meningioma in cell culture and canine cancer patients.

Authors:  Emily J Tonogai; Shan Huang; Rachel C Botham; Matthew R Berry; Stephen K Joslyn; Gregory B Daniel; Zixin Chen; Jianghong Rao; Xiang Zhang; Falguni Basuli; John H Rossmeisl; Gregory J Riggins; Amy K LeBlanc; Timothy M Fan; Paul J Hergenrother
Journal:  Neuro Oncol       Date:  2021-10-01       Impact factor: 13.029

10.  Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synovium.

Authors:  Anak A S S K Dharmapatni; Malcolm D Smith; David M Findlay; Christopher A Holding; Andreas Evdokiou; Michael J Ahern; Helen Weedon; Paul Chen; Gavin Screaton; Xiao N Xu; David R Haynes
Journal:  Arthritis Res Ther       Date:  2009-01-27       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.